ANNUAL REVIEWS
Click here for quick links to Annual Reviews content online, including: Other articles in this volume Top cited articles Top downloaded articles Our comprehensive search
Further
Immune Response to Dengue Virus and Prospects for a Vaccine Brian R. Murphy and Stephen S. Whitehead Laboratory of Infectious Diseases, National Institutes of Allergy and Infectious Diseases, Bethesda, Maryland 20892; email: swhitehead@niaid.nih.gov
Annu. Rev. Immunol. 2011.29:587-619. Downloaded from doc.guandang.net by Shanghai Information Center for Life Sciences on 12/02/13. For personal use only.
Annu. Rev. Immunol. 2011. 29:587–619 First published online as a Review in Advance on January 5, 2011 The Annual Review of Immunology is online at immunol.annualreviews.org This article’s doi: 10.1146/annurev-immunol-031210-101315 0732-0582/11/0423-0587$20.00
Keywords DENV, antibody-dependent enhancement, DHF/DSS, immunization
Abstract Dengue virus (DENV) is a mosquito-borne member of the Flavivirus genus and includes four serotypes (DENV-1, DENV-2, DENV-3, and DENV-4), each of which is capable of causing dengue fever and dengue hemorrhagic fever/dengue shock syndrome. Serious disease can be seen during primary infection but is more frequent following second infection with a serotype different from that of a previous infection. Infection with wild-type DENV induces high-titered neutralizing antibody that can provide long-term immunity to the homotypic virus and can provide short-term immunity (only several months duration) to a heterotypic DENV. The high level of virus replication seen during both secondary infection with a heterotypic virus and during primary DENV infection in late infancy is a direct consequence of antibody-dependent enhancement of replication. This enhanced virus replication is mediated primarily by preexisting, nonneutralizing, or subneutralizing antibodies to the virion surface antigens that enhance access of the virion-antibody complex to FcγR-bearing cells. Vaccines will need to provide longterm protection against each of the four DENV serotypes by inducing neutralizing antibodies, and live, attenuated and various nonliving virus vaccines are in development.
This is a work of the U.S. Government and is not subject to copyright protection in the United States.
587

dengue, suggesting that each Glade may represent ...Sample DNA vaccine for HBV and BCV Wang Quanchu...cellular immune response of immunized mice ...
Host defence Chang Liu Innate immune response ?...VEE, dengue replicate in DCs, which migrate to ...Vaccine strategy with attenuated viruses? ? ...
and Prospects in Cancer Immunotherapy Juhua Zhou ...The human papillomavirus vaccine is protective for ... which elicited an immune response to prostatic ...
His team proposes an AIDS vaccine that would encourage an immune response ...and dengue’, from tinkering’” with mosquito genetics in order to kill ...
a vaccine or specific treatment put a serious ...with serial dilutions of the virus and lethality ...model resembling early immune response to dengue. ...
A DNA vaccine expressing... 12页 2财富值 ...immune response by mechanisms that result in ...virus, dengue virus, Moloney murine leukemia virus...
A DNA vaccine expressing... 12页 2财富值 ...immune response by mechanisms that result in ...virus, dengue virus, Moloney murine leukemia virus...
热门文档